Panbela Therapeutics, Inc. PBLA
At closeNov 4, 2026, 4:00 PM EST
- YTD
- +5,450.00%
- 1 year
- -44.50%
- Market cap
- 53.89K
- EPS (ttm)
- -1,915.86
- Shares out
- 3.48M
- Forward P/E
- -0.02
- YTD return
- +5450.00%
- 1-year return
- -44.50%
- Volume
- 1.01K
- Avg volume
- 756
- Open
- 0.02
- Previous close
- 0.0111
- Day's range
- 0.02 – 0.02
- 52-week range
- 0.0001 – 2.50
- Beta
- 0.82
- Analysts
- Buy
- Price target
- 410.00 (+3693593.7%)
2Y -0.3459 (-96.89%)
Key statistics
- Enterprise value
- 4.48M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.34M
- Total cash
- 907.00K
- Total debt
- 5.19M
- Return on equity
- 0.00%
- Short % of float
- 3.07%
- 50-day average
- 5.07
- 200-day average
- 30.69
Analyst view
Consensus: buy
- Target (low)
- 320.00
- Target (mean)
- 410.00
- Target (high)
- 500.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -24.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.48 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -2.07 | -1.47 | +0.60 | +28.99% |
| May 15, 2024 | Mar 1, 2024 | -1.23 | -2.28 | -1.05 | -85.37% |
| Mar 26, 2024 | Dec 1, 2023 | -24.34 | -65.90 | -41.56 | -170.75% |
| Nov 9, 2023 | Sep 1, 2023 | -41.20 | -53.80 | -12.60 | -30.58% |
| Aug 10, 2023 | Jun 1, 2023 | -94.20 | -159.00 | -64.80 | -68.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 23, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
- Country
- United States
- Website
- panbela.com
News
Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher 
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
Dow Edges Lower; Cardlytics Shares Jump 
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - US Stocks Higher; Accenture Issues Weak Sales Outlook
Your note
Sign in to keep a note on PBLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CULLEN MICHAEL T | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 3, 2022 | 0 |
| FRATAMICO ARTHUR R | Director | Stock Award(Grant) | May 24, 2021 | 9,615 |
| GAGNON SUZANNE | Director | Stock Gift | Apr 28, 2021 | 0 |
| GOLDMAN SACHS GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 7, 2023 | 0 |
| HORVATH SUSAN | Chief Financial Officer | Purchase | Jan 29, 2023 | 17,880 |
| JACOB JEFFREY E | Director | Stock Gift | Sep 11, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 7.97% | 235,819 | 542.38K | Jun 29, 2023 |
| Walleye Capital LLC | 3.20% | 94,536 | 217.43K | Jun 29, 2023 |
| Hudson Bay Capital Management Lp | 2.57% | 76,000 | 174.80K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.13% | 3,713 | 8.54K | Jun 29, 2023 |
| UBS Group AG | 0.03% | 823 | 1.89K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.14% | 4,248 | 9.77K | Jun 29, 2023 |